Several biotechs are exploring STING inhibitors as a means to control innate immunity and inflammation.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
The role of inflammation in neurodegeneration: novel insights into the role of the immune system in C9orf72 HRE-mediated ALS/FTD
Molecular Neurodegeneration Open Access 18 March 2022
-
STING enhances cell death through regulation of reactive oxygen species and DNA damage
Nature Communications Open Access 19 April 2021
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sheridan, C. Drug developers switch gears to inhibit STING. Nat Biotechnol 37, 199–201 (2019). https://doi.org/10.1038/s41587-019-0060-z
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41587-019-0060-z
This article is cited by
-
The role of inflammation in neurodegeneration: novel insights into the role of the immune system in C9orf72 HRE-mediated ALS/FTD
Molecular Neurodegeneration (2022)
-
STING enhances cell death through regulation of reactive oxygen species and DNA damage
Nature Communications (2021)
-
Pharmacological modulation of nucleic acid sensors — therapeutic potential and persisting obstacles
Nature Reviews Drug Discovery (2019)